Market Newsdesk

SAN DIEGO, July 12, 2026 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers of GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026, all dates inclusive (the “Class Period”), have until Monday, August 3, 2026 to seek appointment as lead plaintiff of the GeneDx class action lawsuit. Captioned Basma v. GeneDx Holdings Corp., No. 26-cv-00880 (D. Conn.), the GeneDx class action lawsuit charges GeneDx as well as certain of GeneDx’s top executive officers with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the

GeneDx

class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-genedx-holdings-corp-class-action-lawsuit-wgs.html

You can also contact attorneys

Ken Dolitsky

or

Michael Albert

of Robbins Geller by calling 800/851-7783 or via e-mail at

[email protected]

.

CASE ALLEGATIONS: GeneDx is a genomics company that provides genetic testing services. On April 16, 2025, GeneDx announced an agreement to acquire Fabric Genomics. Fabric Genomics is a firm focused on AI-driven genomic interpretation.

The GeneDx class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose significant problems in Fabric Genomic’s viability that would negatively impact GeneDx’s overall business and operations.

On May 4, 2026, GeneDx announced its 2026 first quarter results, allegedly revealing a drop in adjusted gross margin from 74% to 69%, reduced projected earnings from $540-$555 million to $475-$490 million, and a $31.3 million impairment loss directly attributable to Fabric Genomics. On this news, the price of GeneDx stock dropped over 49%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased GeneDx common stock during the Class Period to seek appointment as lead plaintiff in the GeneDx class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the GeneDx class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the GeneDx class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the GeneDx class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        Ken Dolitsky
        Michael Albert
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800/851-7783
        [email protected]

• The new data demonstrates the potential to improve control of acute infection, latency, and viral reactivation, further supporting the concept behind EVX-V1
• EVX-V1 is a next-generation, multi-component vaccine program combining novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens
• Data presented today in poster presentation at the International Herpesvirus Workshop 2026 taking place in Montreal, Canada

COPENHAGEN, Denmark, July 12, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1.

Data is presented today in a poster session at the International Herpesvirus Workshop (IHW) 2026 taking place in Montreal, Canada.

EVX-V1 is a next-generation, multi-component CMV vaccine program designed with AI-Immunology™. It combines novel protective B-cell antigens and T-cell epitopes complemented by known optimized structural B-cell antigens

This broader multi-targeted strategy is expected to strengthen the protective potential of a future vaccine. The concept represents a scalable strategy for rational vaccine development across other herpesviruses.

“We are excited by the new data which will guide the selection of antigens for a broadly protective CMV vaccine candidate and as such represent an important step forward for the EVX-V1 program. CMV remains a major clinical challenge, causing severe disease in immunocompromised individuals and infants, yet no licensed vaccine exists. EVX-V1 holds the potential to transform the future CMV treatment landscape,” says Birgitte Rønø, CSO and COO of Evaxion.

The new data show that the AI-Immunology™ discovered novel T-cell epitopes have the potential to improve control of acute infection, latency and reactivation in CMV-infected mice. This complements previous findings of the novel B-cell antigens significantly reducing viral infection in preclinical models and the optimized known structural B-cell antigens mediating superior viral neutralization.

About EVX-V1

EVX-V1 is a next-generation, multi-component cytomegalovirus (CMV) vaccine candidate combining novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens. Through this combination, EVX-V1 attacks the virus from multiple, complementary angles. This broader multi-targeted strategy is expected to strengthen the protective potential of the vaccine.

With our AI-Immunology™ platform, we have uncovered novel antigens that are entirely new to the CMV vaccine research field. These previously unexplored CMV-antigens induce specific immune responses, inhibit viral infection and reduce cell-to-cell spread in cellular and animal viral infection models.

EVX-V1 is a combination of these antigens with our proprietary AI-optimized pre-fusion glycoprotein B (gB) antigen which has demonstrated superior performance compared to the traditional gB antigen, including enhanced CMV neutralization.

About CMV

About 1 in 200 babies is born with congenital CMV infection. About 1 in 5 babies with the infection will have congenital disabilities or other long-term health problems. CMV infects approximately 60% to 70% of adults in developed countries and nearly 100% in developing economies, driving demand for CMV treatment. Despite decades of research, no CMV vaccine has been approved to date.

CMV treatment market size was valued at $474.6 million in 2023 and is anticipated to register an annual growth (CAGR) of 6.6% between 2024 and 2032. This growth is propelled by increasing awareness and prevalence of CMV infection and the development of new and effective treatments.

CMV is the most complex of all herpes viruses and is a widespread infection transmitted in body fluids. Once infected, the virus stays for life. People with weakened immune systems, including organ transplant patients, can develop severe symptoms affecting, for example, eyes, lungs, and liver, and congenitally infected babies may suffer from intellectual disability and loss of vision and hearing.

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
[email protected]

About Evaxion

Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development

We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of peak thrombin generation and activated partial thromboplastin time (APTT), and durability supporting potential monthly subcutaneous dosing

HMB-003 program announced as non-hormonal direct plasmin inhibitor with potent, selective and extended antifibrinolytic activity, designed to reduce bleeding across multiple settings beginning in heavy menstrual bleeding

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, July 12, 2026 (GLOBE NEWSWIRE) — Hemab Therapeutics (Nasdaq:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today presented new clinical data from HMB-002 in Von Willebrand disease (VWD) and announced the HMB-003 program at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France.

“Millions of people living with bleeding disorders including VWD and heavy menstrual bleeding have no reliable way to prevent excessive bleeds,” said Benny Sørensen, MD, PhD, CEO of Hemab. “Today, at ISTH 2026 we presented new HMB-002 data demonstrating proof of mechanism in VWD alongside preliminary clinical observations on treated bleeding events. We also unveiled HMB-003, a novel antifibrinolytic built on validated fatty-acid conjugated peptide technology, initially targeting heavy menstrual bleeding – an often-ignored vital sign. It affects one in three women, causing pain, iron-deficiency anemia, fatigue, stigma, and extensive lost days at school and work, with treatment options largely unchanged in decades. HMB-003 is non-hormonal, potent, and selective, engineered to cover the period, then wash out between cycles.”

“The new HMB-002 data support a non-replacement approach in VWD: a single subcutaneous dose raising both VWF and FVIII more than 2-fold, with a favorable safety profile across every cohort,” said Priyanka Raheja, MD, Consultant Haematologist at Barts Health NHS Trust. “Building on 50 years of clinically validated treatment strategy, HMB-002 shows potential to change the VWD treatment paradigm by addressing the root cause of the disease; a durable increase, and for many patients potential normalization, of both VWF and FVIII.”

Program Presentations

HMB-002 is designed to address the underlying biological drivers of VWD through a non-replacement approach—elevating the body’s endogenous levels of VWF and FVIII rather than infusing exogenous factor—with early first-in-human data building a compelling case for this paradigm shift.

• Extended half-life supporting infrequent dosing: Pharmacokinetic (PK) analysis confirmed dose-dependent increase in Cmax with prolonged duration.
• Dual VWF and FVIII elevation: In all dose cohorts tested, VWF and FVIII were elevated in a dose-dependent manner. In cohort A3 (150 mg), ≥2.4-fold elevation in both VWF and FVIII was achieved and accompanied by restoration of thrombin generation, shortening of APTT, and stable multimer distribution. The pharmacokinetic/pharmacodynamic (PK/PD) profile supports potential for monthly dosing.
• Emerging safety profile: Most treatment-emergent adverse events (TEAEs) were mild to moderate in severity, no serious TEAEs occurred, no events were considered related to HMB-002, and no participant discontinued the study due to TEAEs. There were no thromboembolic events, no injection site reactions, no thrombocytopenia, and no hypersensitivity reactions.
• Preliminary clinical observations: The single ascending dose (SAD) part of the study wasn’t designed to measure efficacy, so clinical observations should be considered descriptive in nature. Across the SAD cohorts, 8 of 9 evaluable patients had zero treated bleeds in the 28 days following HMB-002 dosing, with a mean ATBR of 1.6. Among participants treated with HMB-002, the baseline mean ATBR before HMB-002 treatment was 20.1 reflecting significant disease burden in Type 1 VWD, based on bleed data collected up to 5.5 months.

HMB-003 is a novel fatty-acid-conjugated peptide antifibrinolytic, designed to stabilize clots and reduce bleeding across multiple settings, beginning in heavy menstrual bleeding, with preclinical data supporting potent, selective antifibrinolytic activity and extended duration of action.

• Potent and selective plasmin inhibition: HMB-003 directly inhibits plasmin at its active site and inhibits fibrinolysis across both tPA- and uPA-driven pathways, while showing no effect on thrombin generation, platelet function, or coagulation in nonclinical studies.
• Extended antifibrinolytic activity: Following a single subcutaneous dose in minipigs, HMB-003 achieved peak plasma levels within hours and sustained antifibrinolytic activity for approximately one week, supporting the potential for cycle-matched dosing in heavy menstrual bleeding.

About Von Willebrand Disease

Von Willebrand Disease (VWD) is the most common inherited bleeding disorder, characterized by quantitative or qualitative defects in Von Willebrand Factor (VWF), often resulting in frequent mucocutaneous bleeding events and heavy menstrual bleeding in women. The severity of bleeding ranges from low-volume events to potentially life-threatening hemorrhages. Chronic blood loss frequently leads to iron deficiency anemia, exacerbating the disease burden and reducing quality of life, particularly for those with clinically understated subtypes. Despite its prevalence, current treatment options for VWD primarily focus on managing symptoms rather than addressing the underlying biology of the disease.‍

About HMB-002

HMB-002 is a monovalent human antibody being developed as the first-in-class subcutaneous prophylactic treatment for Von Willebrand Disease targeting the underlying cause of the disease, a condition driven by a deficiency or defect in Von Willebrand Factor (VWF), a key regulator of hemostasis. By specifically targeting the C-terminal CK domain of VWF, which is distinct from regions critical to its essential interactions, HMB-002 shields the protein from degradation, boosting endogenous levels without compromising its function. Clinical and nonclinical data suggest strong potential for meaningful therapeutic benefit. For more information, please visit clinicaltrials.gov (NCT06610201 and NCT06754852).

HMB-003

HMB-003 is a subcutaneously administered peptide-based plasmin inhibitor with a durable half-life — a proven therapeutic target in coagulation medicine — being developed as a novel antifibrinolytic designed to reduce bleeding across multiple settings. Engineered to directly inhibit plasmin at its active site, HMB-003 blocks fibrinolysis independently of the plasminogen activation pathway. HMB-003 is optimized to provide sustained bleed protection across multiple high-unmet-need conditions, ranging from heavy menstrual bleeding and hereditary hemorrhagic telangiectasia to peri-operative bleeding management.

About Hemab Therapeutics

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease, and HMB-003, an anti-fibrinolytic targeting plasmin inhibition in preclinical development for multiple high-unmet-need conditions, ranging from heavy menstrual bleeding, hereditary hemorrhagic telangiectasia to peri-operative bleeding management.

Learn more at hemab.com. Follow us on LinkedIn, Facebook, Instagram, and X.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Hemab’s strategy, future operations, prospects and plans, objectives of management, the anticipated timelines for reporting data from Hemab’s clinical trials, the anticipated timelines for initiating a Phase 3 clinical trial of sutacimig and first-in-human studies of HMB-003, the clinical potential of sutacimig, HMB-002 and HMB-003, Hemab’s plans to expand its pipeline, and the sufficiency of Hemab’s cash resources for the period anticipated, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Hemab may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Hemab’s ability to initiate and enroll patients in clinical trials; whether results from preclinical studies and earlier clinical trials will be predictive of the results of later clinical trials; whether Hemab’s cash resources will be sufficient to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Hemab’s filings with the Securities and Exchange Commission (SEC), including the Company’s most recent Form 10-Q and in subsequent filings Hemab may make with the SEC. In addition, the forward-looking statements included in this press release represent Hemab’s views as of the date of this press release. Hemab anticipates that subsequent events and developments will cause its views to change. However, while Hemab may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Hemab’s views as of any date subsequent to the date of this press release.

Media:

Deerfield Group
Peg Rusconi
[email protected]    

Investors:

Hemab Therapeutics
Mads Behrndt
[email protected]

PASCAGOULA, Miss., July 11, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII) christened the future USS George M. Neal (DDG 131), the fourth Flight III Arleigh Burke-class destroyer to be built at the company’s Ingalls Shipbuilding division.

The ship is named for Aviation Machinist’s Mate Third Class George M. Neal, a Korean War veteran and Navy Cross recipient. In 1951, Neal’s helicopter crashed during a rescue attempt in the North Korean mountains. He evaded enemy forces for nine days before being captured and held as a prisoner of war for two and a half years. He was released and returned to the United States in 1952 along with more than 320 fellow prisoners of war.

Performing the duties of the under secretary of the Navy, William Toti delivered the keynote address. “The future USS George M. Neal honors a legacy of extraordinary courage and sacrifice,” Toti said. “As we christen this ship, we mark another step toward building the Navy our nation needs. Flight III destroyers are critical to our nation’s security, and we are proud to accept each one built by the skilled workforce at Ingalls.”

Photos accompanying this release are available at: http://hii.com/news/hii-christens-guided-missile-destroyer-george-m-neal-ddg-131/.

Toti’s remarks highlighted the deep connection between the Navy’s mission and the dedicated Americans who design and build the ships that carry it forward. Building on that message, HII President and CEO Chris Kastner underscored the unique skill and commitment of the Ingalls Shipbuilding team.

“As a company, HII does a lot of amazing things, but only people — human beings — build ships. They build ships with their hands, their minds and toughness. The people of Ingalls Shipbuilding are among the finest craftsmen and craftswomen on the face of the Earth,” Kastner said. “When she is delivered, DDG 131 will be the most powerful surface combatant in the world. She will be ready. She’ll be ready because the United States of America makes a conscious choice, generation after generation for now 250 years, to invest in U.S. Navy ships, built by Americans, in America.”

The ship’s sponsor and daughter of the namesake, Kelley Neal Gray, performed the traditional bottle-breaking ceremony against the bow to formally christen DDG 131. In her remarks, she honored her father’s legacy and expressed gratitude to those who built the ship.

“On behalf of my family, I express my deepest gratitude to the United States Navy, to the incredible honor, for this magnificent destroyer after my father, George Milton Neal,” Gray said. “We are forever grateful that his life of service, sacrifice and courage will be remembered through a ship that will one day defend our nation and carry his legacy throughout the world.”

U.S. Rep. Mike Ezell, representing Mississippi’s 4th District, also addressed ceremony attendees.

“Today’s christening of the future USS George M. Neal is a proud moment for Mississippi and our nation,” Ezell said. “George M. Neal’s courage, sacrifice, and service represent the very best of America, and it is fitting that this warship will carry his legacy for generations to come. I’m grateful to the hardworking men and women of Ingalls Shipbuilding whose craftsmanship strengthens our Navy, supports our Gulf Coast economy, and helps keep our nation safe.”

To date, Ingalls has delivered 36 Arleigh Burke-class destroyers, including the first Flight III, USS Jack H. Lucas (DDG 125), and Ted Stevens (DDG 128). Flight III destroyers currently under construction include Jeremiah Denton (DDG 129), George M. Neal (DDG 131), Sam Nunn (DDG 133), Thad Cochran (DDG 135), and John F. Lehman (DDG 137). Ships in pre-planning include Telesforo Trinidad (DDG 139), Ernest E. Evans (DDG 141), Charles French (DDG 142), Richard J. Danzig (DDG 143), Intrepid (DDG 145), Robert Kerrey (DDG 146), and Ray Mabus (DDG 147).

Flight III Arleigh Burke-class destroyers represent the next generation of surface combatants and incorporate a number of design modifications that collectively provide significantly enhanced capability. Upgrades include the AN/SPY-6(V)1 Air and Missile Defense Radar (AMDR) and the Aegis Baseline 10 Combat System required to keep pace with the threats well into the 21st century.

Video of the ceremony, along with additional information on DDG 131 and the Arleigh Burke-class program, is available at www.hii.com/events/DDG131.

About HII

HII is America’s largest shipbuilder, delivering the world’s most powerful ships and all-domain mission technologies, including unmanned systems, to U.S. and allied defense customers. HII is the largest producer of unmanned underwater vehicles for the U.S. Navy and the world.

With a more than 140-year history of advancing U.S. national security, HII builds and integrates defense capabilities extending from the core fleet to C6ISR, AI/ML, EW and synthetic training. Headquartered in Virginia, HII’s workforce is 44,000 strong. For more information, visit:

• HII on the web: https://www.HII.com/
• HII on Facebook: https://www.facebook.com/TeamHII
• HII on X: https://www.twitter.com/WeAreHII
• HII on Instagram: https://www.instagram.com/WeAreHII
• HII on LinkedIn: https://www.linkedin.com/company/wearehii

Contact:

Kimberly K. Aguillard
[email protected]
228-355-5663

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/173938d8-a6b0-484d-b1b9-dcf22b5e76f5

SEATTLE, July 10, 2026 (GLOBE NEWSWIRE) — Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology company that provides essential marketing and sales solutions, today announced that it has commenced an underwritten public offering of its Class A common stock (or pre-funded warrants to purchase shares of Class A common stock in lieu thereof). All of the securities in the proposed offering are being offered by Banzai. The aggregate offering amount of the securities issued in the proposed offering, including any securities issued pursuant to an underwriter’s option, approximately $1 million, which is the maximum market value of securities that Banzai is allowed to sell under “baby shelf” rules currently applicable to its effective shelf registration statement on Form S-3.

The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Banzai intends to use the net proceeds from the proposed offering for working capital and other general corporate purposes.

Aegis Capital Corp. is acting as the sole book-running manager for the proposed offering.

The offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-288908) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on August 8, 2025. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at [email protected], or by telephone at +1 (212) 813-1010.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About
Banzai

Banzai is a marketing technology company that provides AI-enabled marketing and sales solutions for businesses of all sizes. On a mission to help their customers grow, Banzai enables companies of all sizes to target, engage, and measure both new and existing customers more effectively. Banzai has over 150,000 customers including Amazon, Dell, Salesforce, Aflac, Thermo Fisher Scientific, RBC Wealth Management, and Fitch Group. Learn more at www.banzai.io. For investors, please visit ir.banzai.io.

Forward-Looking
Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often use words such as “believe,” “may,” “will,” “estimate,” “target,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “propose,” “plan,” “project,” “forecast,” “predict,” “potential,” “seek,” “future,” “outlook,” and similar variations and expressions. Forward-looking statements are those that do not relate strictly to historical or current facts. Examples of forward-looking statements may include, among others, statements regarding Banzai International, Inc.’s (the “Company’s”): expectations regarding the timing and size of the offering and sale of securities, the Company’s ability to complete the offering, future financial, business and operating performance and goals; annualized recurring revenue and customer retention; ongoing, future or ability to maintain or improve its financial position, cash flows, and liquidity and its expected financial needs; potential financing and ability to obtain financing; acquisition strategy and proposed acquisitions and, if completed, their potential success and financial contributions; strategy and strategic goals, including being able to capitalize on opportunities; expectations relating to the Company’s industry, outlook and market trends; total addressable market and serviceable addressable market and related projections; plans, strategies and expectations for retaining existing or acquiring new customers, increasing revenue and executing growth initiatives; and product areas of focus and additional products that may be sold in the future. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity and development of the industry in which the Company operates may differ materially from those made in or suggested by the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements. Factors that may cause actual results to differ materially include changes in the markets in which the Company operates, customer demand, the financial markets, economic, business and regulatory and other factors, such as the Company’s ability to execute on its strategy. More detailed information about risk factors can be found in the Company’s Annual Report on Form 10-K and the Company’s Quarterly Reports on Form 10-Q under the heading “Risk Factors,” and in other reports filed by the Company, including reports on Form 8-K. The Company does not undertake any duty to update forward-looking statements after the date of this press release.

Investor
Relations

Dean Ditto
Chief Financial Officer, Banzai
206 414-1777
ir.banzai.io

Media

Paul Witkowski
Senior Director Financial Reporting, Banzai
[email protected]